For decades, "Longevity" was the domain of clinicians and biologists. The conversation was dominated by supplements, diets, and the search for "Blue Zones."

But as we move into 2025/2026, Longevity is shifting from a biological challenge to a Systems Engineering challenge. We are entering the era of "Healthspan Architecture."

The emerging $600 Billion Longevity Economy is not just about curing disease; it is about restructuring society, finance, and infrastructure to support a population that lives to 100 as the new normal. This requires a new breed of professional—one who understands the science but speaks the language of venture capital and regulation.

Why We Built the Master in Regenerative Biotech Strategy

We observed a critical talent gap. Biotech startups are full of brilliant scientists who struggle to navigate FDA regulatory pathways for "aging as an indication." Conversely, venture capital firms are full of financial wizards who cannot discern between a viable epigenetic clock and snake oil.

Our Master in Regenerative Biotech Strategy & Translational Longevity was architected to bridge this gap. We focus on the "Non-Clinical" pillars that actually determine success or failure:

  • Translational Strategy: How do you move a molecule from the lab to a viable product?

  • Regulatory Architecture: How do you design trials for decentralized, AI-driven biomarkers?

  • Venture Governance: How do you structure IP and funding for deep-tech moonshots?

We are not training you to hold a pipette. We are training you to hold the boardroom accountable. The future of longevity belongs to the strategists who can connect the dots between synthetic biology and systemic implementation.

View the Master in Regenerative Biotech Strategy →